About Event

Gene Therapy for Ophthalmic Disorders is dedicated to overcoming delivery and drug development challenges encountered in the development of gene therapies for ophthalmic diseases.

Virtually uniting dedicated and experienced professionals across the ophthalmology space, this event addresses key hurdles to overcome, including:

Transparent

Delivering Gene Therapies Effectively to the Retina
Learn how Clearside Biomedical are progressing suprachoroidal delivery with the potential to minimize invasive surgical procedures

Transparent

Validating Clinical Endpoints that Satisfy the Regulators
Discover how to  develop novel clinical endpoints that are meaningful to patients and regulatory bodies from REGENXBIO

Transparent

Pioneering Novel Vectors with Enhanced Efficacy and Safety
Gain key vector insights from Eyevensys, who are developing non-viral vectors to minimize immune response and increase likelihood or re-dosing

Transparent

Discovering the Latest Advances in Preclinical Models
Utilize knowledge from Novartis to assess toxicity, safety, and dosing levels in preclinical models and effectively translate to the clinic

Transparent

Designing Effective Clinical Trials from Phase I to Phase III
Explore the realities of clinical trial design to meet regulatory expectations throughout a program, with insights from Gensight Biologics